GET DAILY SIGNALSMolina Healthcare (MOH) Posts Q3 Beat but Shares Fall -5.5% on Margin Concerns
Key Takeaways
- Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share, topping the FactSet consensus estimate of $0.79 by $0.10.
- Total revenue came in at $11.08 billion, above the $10.86 billion consensus, though it declined 3.4% from $11.48 billion a year earlier.
- GAAP net income fell 52% to $38 million, or $0.73 per share, from $79 million, or $1.51 per share, in the prior-year quarter, reflecting higher medical costs.
- Management reaffirmed full-year 2026 adjusted EPS guidance of $5.25 and held premium revenue guidance at roughly $42 billion.
- Total membership continued to shrink, driven by a steep decline in Marketplace enrollment, while the consolidated medical care ratio rose year over year.
- The stock slipped roughly 5.5% after the release as investors weighed the headline beat against ongoing margin pressure.
Why This Quarter Matters
Molina Healthcare is one of the largest Medicaid-focused managed care organizations in the United States, which makes its quarterly results a closely watched barometer for government-sponsored health insurance. The company has spent the past several quarters contending with falling enrollment following the end of pandemic-era Medicaid protections, alongside elevated medical costs. This quarter was important because investors were looking for evidence that Molina's margin challenges are stabilizing and that its planned 2027 recovery remains on track. With the stock trading well above its 52-week low, the market had already begun pricing in a rebound, making the details of this report especially significant for the outlook. To get a broader view of how MOH stacks up against peers, I also checked this using Tickeron’s AI Screener.
The Quarter in Detail
Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share, exceeding the FactSet consensus estimate of $0.79 per share. Total revenue of $11.08 billion also topped the $10.86 billion consensus. On a GAAP (generally accepted accounting principles) basis, however, net income fell 52% to $38 million, or $0.73 per share, compared with $79 million, or $1.51 per share, in the same period last year. Adjusted net income was $46 million.
The decline reflects a meaningful contraction in the business. Premium revenue of approximately $10.46 billion fell about 4% year over year as membership shrank. The consolidated MCR (medical care ratio, which measures medical costs as a percentage of premium revenue) rose year over year, and the company's Medicaid segment, its largest, also saw its MCR climb. Total ending membership declined to roughly 4.86 million from about 5.63 million a year earlier, with Marketplace enrollment falling sharply from approximately 713,000 to 267,000 members.
Despite the pressures, management reaffirmed full-year 2026 adjusted EPS guidance of $5.25 and left premium revenue guidance unchanged at approximately $42 billion. The quarter also included a non-cash impairment charge tied to the company's decision to exit its Medicare Advantage Prescription Drug (MAPD) product in 2027, part of a strategic shift to focus on dual-eligible members.
Market Reaction and Investor Sentiment
The market's initial response was cautious. Despite the double beat on earnings and revenue, shares of MOH declined about 5.5% in after-hours trading following the release, suggesting that investors were more focused on the underlying margin squeeze than on the headline figures. A 52% drop in GAAP net income and a rising consolidated MCR signaled that the company is still absorbing higher medical costs and shrinking membership.
The muted reaction echoed the prior quarter, when an earnings beat was similarly overshadowed by concerns about the operating picture. Heading into this report, analyst sentiment had turned more cautious, with consensus estimates revised downward in the weeks before the release. The stock's decline after the print indicates that the market remains skeptical until there is clearer evidence that Medicaid margins are turning.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central question is whether Molina Healthcare can deliver the margin recovery that the market has already begun to price in. CEO Joseph Zubretsky indicated that the company is seeing an apparent plateauing of medical cost trend and that the strength of 2027 rate updates suggests Molina may be "likely observing the beginning of the turn in Medicaid margins." That commentary will be a key benchmark for investors in the quarters ahead.
Membership trends will remain critical. Medicaid enrollment has been declining industry-wide, and investors should watch whether that contraction stabilizes ahead of new work requirements taking effect in 2027. The company's strategic exit from its Medicare Advantage Prescription Drug product is also worth monitoring, as it reflects a deliberate narrowing of focus toward dual-eligible members.
Finally, cost management will be the defining factor. With the consolidated MCR still elevated, any further uptick in medical costs could quickly erode the thin margin between premiums and claims. Reaffirmed full-year guidance of $5.25 in adjusted EPS provides a floor for near-term expectations, but the trajectory of 2027 rates and medical cost trends will ultimately determine whether the anticipated recovery materializes. Investors will be watching upcoming earnings for confirmation that margins are improving rather than merely stabilizing.
AI Tools in My Research Process
In my own work, I regularly use Tickeron’s AI Screener to quickly filter for stocks showing similar technical patterns or fundamental shifts in the managed care space. It helps surface comparable names and monitor signals without spending hours on manual screens, which keeps my analysis focused on the key drivers like medical cost trends and enrollment changes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MOH in upward trend: 10-day moving average moved above 50-day moving average on October 15, 2026
The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on MOH as a result. In 53 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for MOH just turned positive on October 06, 2026. Looking at past instances where MOH's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
MOH moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 211 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for MOH moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 22 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
MOH broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MOH entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating fairly steady price growth. MOH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.689) is normal, around the industry mean (3.597). MOH's P/E Ratio (1343.125) is considerably higher than the industry average of (133.056). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health care services to persons eligible for Medicaid
Industry ManagedHealthCare
Advertisement